Emergent BioSolutions reported Q1 2026 revenues of $156.1 million, a 30% decline from the previous year, with net income of $6.8 million and an adjusted EBITDA of $35.6 million. The company highlighted strategic partnerships, debt refinancing to reduce interest expenses, and new product launches like NARCAN® carrying cases. Despite revenue declines mainly due to timing and volume changes in government contracts, Emergent maintains its 2026 revenue guidance of $720-$760 million and raised its adjusted EBITDA forecast to $155-$175 million. The company continues to focus on biodefense and opioid overdose products while executing a multi-year transformation plan.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
Gnosis (GNO) surged 13% in 24 hours, closing in on overtaking BONK by market capitalization to reach the 100th largest token spot. GNO's market cap stands at $303.88 million versus BONK's $330.07 million, requiring a price rise to about $125.48 for t...
Broadridge's Tokenization Pulse Survey shows 84% of firms view tokenization as strategically important, with 68% expecting it to reshape markets within 3-5 years. Most firms plan to integrate tokenization into existing infrastructure rather than buil...
Standard Chartered has partnered with Broadcom to modernize its global banking infrastructure by adopting a secure, resilient private cloud using VMware Cloud Foundation. This upgrade supports critical banking services across 54 markets with enhanced...
